Reports Q4 revenue $29.55M, consensus $26.02M. Michael McGarrity, CEO of mdxhealth (MDXH), commented: “We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consistent growth is a result of our strategy to build an incomparable menu of precision diagnostics for urologists and patients navigating the complex diagnostic pathway of prostate cancer.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- MDxHealth Details Exosome Diagnostics Deal and Restructured GPS Earnout Obligations
- MDxHealth: Strengthening Fundamentals, Above-Consensus 2026 Outlook, and Undervalued Growth Support Buy Rating
- MDxHealth Posts Strong 2025 Revenue Growth, Sets 2026 Outlook and Revises Exact Sciences Earnout
- MDxHealth sees Q4 revenue $30.5M, consensus $26.18M
- MDxHealth announces next phase of collab with University of Oxford